Welcome to our dedicated page for Danaher news (Ticker: DHR), a resource for investors and traders seeking the latest updates and insights on Danaher stock.
Danaher Corporation reports developments tied to its global life sciences and diagnostics businesses, where its companies provide scientific technologies, clinical diagnostic systems and tools used in discovery, diagnosis and therapy development. Recurring updates include earnings calls, dividend actions, investor conference appearances and product or regulatory milestones from operating businesses such as Beckman Coulter Diagnostics.
Company news also covers diagnostic assays, immunoassay analyzer platforms, clinical-laboratory workflows and the Danaher Business System, which the company uses as an operating framework across its businesses. Additional recurring themes include shareholder voting matters, governance updates and capital-structure disclosures.
Danaher Corporation (NYSE: DHR) reported robust Q1 2021 results, showcasing net earnings of $1.7 billion or $2.29 per diluted share, marking a 182.5% year-over-year increase. Revenues surged 58.0% to $6.9 billion, with 30.0% non-GAAP core revenue growth including Cytiva. Operating cash flow reached $1.9 billion, a 126.5% rise year-over-year. Looking ahead, Danaher expects mid-20% non-GAAP core revenue growth for Q2 and high-teens growth for the full year. CEO Rainer M. Blair highlighted strong market performance driven by contributions to COVID-19 related developments.
Danaher Corporation (NYSE: DHR) announced that its first quarter 2021 core revenue growth exceeded expectations, with total revenue growth at approximately 57.0% and non-GAAP core revenue growth including Cytiva at 29.0%. This strong performance was attributed to significant growth in the Life Sciences and Diagnostics segments. The company will discuss these results in its earnings conference call on April 22, 2021. The non-GAAP measures mentioned will aid investors in understanding underlying growth trends.
Danaher Corporation (NYSE: DHR) is scheduled to host its first-quarter 2021 earnings conference call on April 22, 2021, at 8:00 a.m. ET. The call will be available on Danaher’s website, along with a slide presentation. A replay of the call will be accessible until May 6, 2021. Investors can join the call by dialing 866-503-8675 in the U.S. or +1 786-815-8792 outside the U.S. The earnings press release and related materials will be available on their website by 6:00 a.m. ET on the day of the call.
Beckman Coulter announced that its Access SARS-CoV-2 IgG II antibody assay has received U.S. Emergency Use Authorization (EUA) from the FDA. This semi-quantitative test measures antibody levels post-SARS-CoV-2 infection, delivering results that will help clinicians monitor patients' immune responses. The assay boasts a 99.9% specificity and 98.9% sensitivity. Available in the U.S. and countries accepting the CE Mark, it integrates into existing workflows and can process up to 4,800 samples per day using the DxI 800 analyzer. Beckman Coulter aims to enhance COVID-19 diagnostics.
Beckman Coulter announced its commitment to support the U.S. government's plan to invest over $12 billion in COVID-19 testing by providing a high-throughput, $4 antigen test, Access SARS-CoV-2 Ag, aimed at mass screening. This test boasts a 93% positive predictive agreement and a 100% negative predictive agreement, with results available in 30 minutes. Targeted for high-risk settings, the test promotes equity in COVID-19 testing and aids in reopening schools and businesses safely.
Danaher Corporation (NYSE: DHR) announced that Executive Vice President and Chief Financial Officer, Matt McGrew, will present at the Barclays Global Healthcare Conference on March 11, 2021, at 11:30 a.m. ET. The presentation will be available via a simultaneous webcast on Danaher's official website.
Danaher is a leading global innovator in science and technology, focusing on complex challenges in healthcare, environmental, and applied markets. The company employs around 69,000 associates and operates more than 20 companies under the Danaher Business System.
On February 23, 2021, Danaher Corporation (NYSE: DHR) announced the approval of a quarterly cash dividend of $0.21 per share for common stock, payable on April 30, 2021, to shareholders of record by March 26, 2021. Additionally, the company approved dividends for its preferred stock, including $11.875 per share for 4.75% Series A and $12.50 per share for 5.00% Series B, both payable on April 15, 2021, to holders of record by March 31, 2021.
Danaher Corporation (NYSE: DHR) announced that its President and CEO, Rainer M. Blair, will speak at the Cowen Healthcare Conference on March 1, 2021, at 11:40 a.m. ET. The presentation will be accessible via a live webcast on www.danaher.com. Danaher is a prominent global innovator in science and technology, focusing on solving complex challenges in healthcare and other sectors, supported by its diverse workforce of about 69,000 associates.
Cytiva has acquired Vanrx Pharmasystems, a Canadian firm specializing in robotic aseptic filling machines, marking its first acquisition since becoming an operating company of Danaher in April 2020. This acquisition aligns with global trends towards smaller batch manufacturing and personalized therapies in the growing USD 300 billion biologics market. The addition enhances Cytiva's solutions from drug development to drug product, facilitating faster delivery of therapies to patients. Vanrx's expertise in aseptic filling complements Cytiva's existing manufacturing capabilities.
Danaher Corporation (NYSE: DHR) reported strong financial results for Q4 and full year 2020. Q4 net earnings reached $1.2 billion ($1.66 per share), up 55% year-over-year, while revenues climbed 39% to $6.8 billion. Full year net earnings totaled $3.6 billion ($4.89 per share), reflecting a 50% increase, with total revenues at $22.3 billion, a 24.5% rise. The company anticipates mid to high-teens non-GAAP core revenue growth for Q1 2021 and low-double digits for the full year. The acquisition of Cytiva significantly bolstered Danaher's market position and long-term value.